Tango Therapeutics and Revolution Medicines Report Strong Combo Trial for Pancreatic Cancer

By Adam Feuerstein · STAT News · 2026-10-23

STAT News reports that a combination therapy utilizing vopimetostat and Rasonque achieved high response rates in patients with a specific form of advanced pancreatic cancer. Clinical trial data presented at the ESMO conference suggests that this dual-target approach may provide a

STAT News reports that a combination therapy utilizing vopimetostat and Rasonque achieved high response rates in patients with a specific form of advanced pancreatic cancer. Clinical trial data presented at the ESMO conference suggests that this dual-target approach may provide a